Abstract 441P
Background
Both Western and Chinese medicine, despite different in methods and systems, are well accepted in Hong Kong. According to a survey on cancer patients in Hong Kong conducted by the Hong Kong Baptist University in 2009, 57% of cancer patients used at least one form of Chinese Medicine therapy. Among those who were on chemotherapy, 60% of them are concurrently receiving Traditional Chinese Medicine (TCM) herbal therapy. This pilot study addressed the problem of hepatotoxicity of concurrent Traditional Chinese Medicine (TCM) herbal therapy use, which is the major hurdle of integrated Chinese-Western medicine practice in cancer medicine. We evaluated the difference in incidence of liver toxicity of cancer patients receiving systemic therapy with or without concurrent TCM herbal therapy.
Methods
187 patients were prospectively recruited in the Department of Clinical Oncology of Queen Mary Hospital. Through questionnaires and the online Clinical Management System (CMS), they were followed up for 3 months, their current Western systemic therapy, TCM herbal therapy taken, and liver function tests results (bilirubin, ALT, AST, ALP) were retrieved. Patients were divided into the TCM herbal therapy and non-TCM herbal therapy group, depending on whether TCM herbal therapy was taken concurrently with systemic therapy. Liver function derangement was graded by CTCAE v4.0. The differences between the TCM herbal therapy and non-TCM herbal therapy groups were analysed by Pearson’s chi square test and Mann-Whitney U tests. Multivariable analysis was performed by Cox proportional hazard models to identify the prognostic factors for TCM herbal therapy coverage.
Results
There was no significant difference of liver toxicity incidence between the TCM herbal therapy and non-TCM herbal therapy group(P = 0.577). No prognostic factors (age and sex) were identified for TCM herbal therapy coverage.
Conclusions
The results of our pilot study suggest that concurrent TCM herbal therapy usage by cancer patients does not increase the risk of liver toxicity. Our results warrant further prospective studies to confirm the finding.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
248P - Retrospective review of metastatic carcinoma of cervix from a tertiary cancer institute of south India
Presenter: Arkoprovo Halder
Session: Poster display session
Resources:
Abstract
249P - Accuracy of endometrial biopsy by Pipelle: A systematic review and meta-analysis
Presenter: Jinhai Gou
Session: Poster display session
Resources:
Abstract
250P - Non-endometrioid endometrial cancer: Analysis of different adjuvant treatment modalities
Presenter: Gonçalo Nogueira da Costa
Session: Poster display session
Resources:
Abstract
251P - A prognostic index model for predicting long-term recurrence of uterine leiomyoma after initial myomectomy in women aged 18-44 years
Presenter: Xiu Ming
Session: Poster display session
Resources:
Abstract
252P - Uterine sarcomas in Qatar: Clinico-pathological characteristics and treatment outcome
Presenter: Ashraf Fadlelseid
Session: Poster display session
Resources:
Abstract
253P - Anti-PD-1-induced reinvigoration of tumour-infiltrating CD8+ T cells in epithelial ovarian cancer patients is correlated with T cell factor-1
Presenter: Junsik Park
Session: Poster display session
Resources:
Abstract
254P - Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)
Presenter: Diar Aziz
Session: Poster display session
Resources:
Abstract
255P - MEX3A is a prognostic biomarker and correlates with RNA splicing and cell proliferation in endometrial cancer by analysis of RNA-seq data
Presenter: Huining Jing
Session: Poster display session
Resources:
Abstract
256P - Lnc-AL445665.1-4 may be involved in the development of multiple uterine leiomyoma through interacting with miR-146b-5p
Presenter: E Yang
Session: Poster display session
Resources:
Abstract
257P - Treatment results of low risk gestational trophoblastic neoplasia (GTN) from a tertiary hospital, Chennai, India
Presenter: Rakesh M. P
Session: Poster display session
Resources:
Abstract